CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more

Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’ experimental CAR-T therapy. Novartis has paused immunology and neuroscience studies for the drug, and ...